NUMARZU-001 / Hospital Clinic of Barcelona - LARVOL DELTA

Adoptive PD1+ tumor-infiltrating lymphocyte therapy for metastatic TNBC: First results of the safety run-in phase of the TILS001 clinical trial (ESMO-BC 2024) - P1/2 | "Conclusions NUMARZU-001 has shown a manageable safety profile in the safety run-in phase. The independent safety data monitoring committee recommended continuing recruitment to expand the pool of treated patients and evaluate its efficacy further."

Clinical • IO biomarker • Metastases • Tumor-infiltrating lymphocyte • Anemia • Anorexia • Cardiovascular • CNS Disorders • Heart Failure • Hematological Disorders • Mental Retardation • Neutropenia • Oncology • Psychiatry • Triple Negative Breast Cancer • PD-1

TILS001: Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Fundacio Clinic Barcelona | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-1

TILS001: Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (clinicaltrials.gov) - P1/2 | N=20 | Not yet recruiting | Sponsor: Fundacio Clinic Barcelona

New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-1